By Dr. Jennifer Frangos, D.O. Updated November 2026.
Most side effects from estradiol vaginal cream happen right where you put it: burning, itching or irritation, and sometimes a yeast infection. Breast pain, headache, bloating and nausea are on the list too. The ones not to sit on are bleeding, a new breast lump, and the stroke or clot warning signs in the table below.
If you opened the leaflet and saw a big black box about cancer, heart disease and dementia, that box is in the middle of a change. The FDA asked for the whole box to come off vaginal estrogen labels in November 2025, but as of November 2026 the estradiol cream labels haven’t been updated yet.
Normal, call soon, or call 911: a quick sort
Here’s a simple way to sort what you might notice. The first four rows come from the Estrace leaflet’s own lists; the last row comes from the CDC’s heart attack and stroke guidance.
| What you notice | What to do |
|---|---|
| Burning, itching or irritation when you insert it, breast tenderness, headache, bloating, nausea | Listed as common and less serious. Bring it up at your next check-in, or sooner if it isn’t settling or it’s keeping you from using the cream. |
| Itching or discharge that seems like a yeast infection | Common on the label. Let your provider know so it can be checked and treated, rather than waiting it out. |
| Any vaginal bleeding or spotting | The leaflet says to report unusual vaginal bleeding right away. After menopause, bleeding can be a warning sign of uterine cancer and usually needs a workup. |
| A new breast lump, changes in vision or speech, a sudden new severe headache, severe chest or leg pain, swollen lips, tongue or face | The leaflet calls these warning signs. Call your provider right away. |
| Chest pain or discomfort with shortness of breath, or sudden numbness or weakness on one side, or sudden trouble speaking | These can be a heart attack or stroke. Call 911. |
About the bleeding row: the Estrace label says vaginal bleeding after menopause may be a warning sign of cancer of the uterus, and it tells clinicians to rule that out in postmenopausal women with persistent or recurring abnormal bleeding, including sampling of the uterine lining when indicated.
If side effects have you second-guessing vaginal estrogen, or dryness is one piece of a bigger set of menopause changes, talk it through with our care team on a free call, and we’ll work out where to start.
The common side effects
The Estrace (estradiol vaginal cream) leaflet calls these “less serious, but common”:
- Burning, irritation or itching from inserting the cream
- Vaginal yeast infection
- Breast pain
- Headache
- Stomach or abdominal cramps and bloating
- Nausea and vomiting
- Irregular vaginal bleeding or spotting
- Fluid retention
- Hair loss
The leaflet doesn’t say how often any of these happen. The best numbers available come from a different low-dose product. In a 12-month trial of an estradiol vaginal insert, 8% of women on the insert got a vaginal yeast infection, compared with 3% on placebo, and 8% had vaginal itching, compared with 2%. That was an insert, not cream, so treat these as a rough guide rather than your odds.
Across the studies reviewed for the 2025 AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause, vaginal estrogen was associated with vaginal bleeding, discharge and breast tenderness.
Is it the cream, or the problem you’re treating?
Dryness, burning and irritation are also symptoms of genitourinary syndrome of menopause (GSM), the condition the cream is prescribed for. So before your follow-up, jot down two things: did the burning start before or after you began the cream, and is it in the same spot as before? That timing helps your provider tell a side effect apart from the symptoms the cream is meant to treat. A change in discharge or odor is worth mentioning too; our post on vaginal odor during menopause walks through the usual causes.
Do you need progesterone with vaginal estrogen?
Progesterone (or a progestin) is there to protect the lining of the uterus. The Estring label notes that using systemic estrogen alone raises the risk of endometrial cancer in women with a uterus, and that adding a progestogen reduces the risk of endometrial hyperplasia. That’s why women with a uterus who take estrogen pills, patches or gel for hot flashes usually take progesterone too.
Low-dose vaginal estrogen is a different situation. The AUA guideline tells clinicians to counsel patients that local low-dose vaginal estrogen does not increase the risk of endometrial hyperplasia with atypia or endometrial cancer, and says not to monitor the lining just because someone uses it. Those statements are about low-dose use, so the Estrace leaflet’s advice still applies: if you have a uterus, ask your provider whether adding a progestin makes sense for you. If you’ve had a hysterectomy, the question mostly goes away; our post on HRT after a hysterectomy covers that side.
What if you’ve had breast cancer?
This is where the label and the newer guideline part ways. The Estrace label lists known, suspected or past breast cancer as a reason not to use the cream. The AUA guideline tells clinicians to explain that there’s no evidence linking local low-dose vaginal estrogen to developing breast cancer, and it allows low-dose vaginal estrogen for survivors through multidisciplinary shared decision-making. In practice, your oncology team should be part of that conversation before anyone writes a prescription, especially if you’re still on a hormone-blocking medicine.
Why your leaflet may still have a boxed warning
On November 10, 2025, the FDA asked the makers of all menopausal hormone therapies, both systemic and local vaginal products, to change their labels. For every product, vaginal estrogen included, the FDA asked companies to:
- Remove cardiovascular disease, breast cancer and probable dementia from the boxed warning
- Remove endometrial cancer from the boxed warning, except on systemic estrogen-alone products
- Remove the advice to use the “lowest effective dose for the shortest amount of time” from the boxed warning
- Remove the probable dementia warning from the label
For local vaginal products only, the FDA also asked companies to condense the safety information and put what matters most for vaginal use first. The endometrial cancer box stays only for systemic (whole-body) estrogen-alone products, not vaginal cream. The Menopause Society said it agreed with removing the boxed warning on low-dose vaginal estrogen, and that the box may have discouraged women from using it.
A request isn’t the same as a new label, though. Each company has to submit its revised label and get it approved. On February 12, 2026, the FDA approved the first six updated labels, out of submissions from 29 companies. Here’s where things stood when we checked on November 7, 2026:
- The FDA’s list of updated labels (last updated October 30, 2026) names nine products. The only vaginal one is Estring, the low-dose ring, and its revised label has no boxed warning at all.
- No estradiol vaginal cream is on that list. The Estrace label on DailyMed (revised May 2024) still opens with the old box covering endometrial cancer, cardiovascular disorders, breast cancer and probable dementia. So do the generic cream labels we checked, including one revised in December 2025 and one revised in March 2026.
If your leaflet opens with a boxed warning, it tells you that label hasn’t been revised yet. It doesn’t mean your cream was singled out, since the FDA’s request covered every vaginal estrogen product. Your provider can walk you through what actually applies to vaginal use.
A note on compounded estradiol creams
Some estradiol creams are mixed by compounding pharmacies and never go through FDA approval. The FDA says it does not have evidence that compounded “bioidentical hormones” are safe and effective, or safer or more effective than FDA-approved hormone therapy. Everything on this page comes from approved products. Our post on BHRT vs. HRT compares the two.
Vaginal estrogen and the rest of your menopause care
Amazing Meds prescribes vaginal estradiol cream. If vaginal dryness or painful sex is one of several menopause changes you’re dealing with, your provider here looks at the whole list, along with whatever you already use. If your vaginal estrogen comes from your own gynecologist, you can keep it there and still see us for testosterone. You can read how getting started works before you book anything.
Frequently asked questions
Is spotting normal on estradiol vaginal cream?
Spotting is on the label’s list of common side effects, but the same leaflet says to report unusual vaginal bleeding right away. After menopause, bleeding of any amount should be checked, because it can be a warning sign of uterine cancer.
Does estradiol vaginal cream still have a black box warning?
As of November 7, 2026, yes. The FDA asked in November 2025 for the boxed warning to come off vaginal estrogen labels, but the Estrace label and the generic cream labels on DailyMed haven’t been revised yet. The Estring ring is the only vaginal product with an updated label so far.
Can estradiol vaginal cream cause weight gain?
The Estrace label lists fluid retention as a common side effect and lists weight increase or decrease among reported reactions. Severe leg pain is different: the leaflet lists it as a warning sign to report right away.
Can I use estradiol vaginal cream after breast cancer?
Possibly, but not on your own. The Estrace label says no, while the 2025 AUA guideline allows low-dose vaginal estrogen for survivors through shared decision-making with your care team. Your oncologist should be part of that decision.
Have your tube or leaflet handy, along with a short list of any side effects you’ve noticed and when they started, for your free call with our care team.
Sources
- DailyMed, US National Library of Medicine. Estrace (estradiol vaginal cream) prescribing information and patient information, revised May 2024. Link
- DailyMed, US National Library of Medicine. Estradiol Vaginal Cream USP prescribing information, revised December 2025. Link
- DailyMed, US National Library of Medicine. Estradiol Vaginal Cream USP prescribing information (repackaged), revised March 2026. Link
- US Food and Drug Administration. Vagifem (estradiol vaginal inserts) prescribing information, 2022. Link
- US Food and Drug Administration. Estring (estradiol vaginal system) prescribing information, revised February 2026. Link
- Kaufman MR, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline, 2025. Link
- US Food and Drug Administration. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies, November 10, 2025. Link
- US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026. Link
- US Food and Drug Administration. Menopausal Hormone Therapies with Updated Prescribing Information, content current as of October 30, 2026. Link
- The Menopause Society. The Menopause Society Comments on the FDA Announcement on Hormone Therapy, November 10, 2025. Link
- US Food and Drug Administration, Office of Women’s Health. Menopause. Link
- Centers for Disease Control and Prevention. About Heart Attack Symptoms, Risk, and Recovery. Link
- Centers for Disease Control and Prevention. Signs and Symptoms of Stroke. Link
This article is for general education and is not medical advice. Talk with a licensed provider about your own health before starting, stopping or changing any treatment.
